Literature DB >> 30309862

Mouse Models for Cancer Immunotherapy Research.

Brian Olson1, Yadi Li1, Yu Lin1, Edison T Liu2, Akash Patnaik3.   

Abstract

Immunotherapy has revolutionized cancer therapy, largely attributed to the success of immune-checkpoint blockade. However, there are subsets of patients across multiple cancers who have not shown robust responses to these agents. A major impediment to progress in the field is the availability of faithful mouse models that recapitulate the complexity of human malignancy and immune contexture within the tumor microenvironment. These models are urgently needed across all malignancies to interrogate and predict antitumor immune responses and therapeutic efficacy in clinical trials. Herein, we seek to review pros and cons of different cancer mouse models, and how they can be used as platforms to predict efficacy and resistance to cancer immunotherapies.Significance: Although immunotherapy has shown substantial benefit in the treatment of a variety of malignancies, a key hurdle toward the advancement of these therapies is the availability of immunocompetent preclinical mouse models that recapitulate human disease. Here, we review the evolution of preclinical mouse models and their utility as coclinical platforms for mechanistic interrogation of cancer immunotherapies. Cancer Discov; 8(11); 1358-65. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30309862      PMCID: PMC8725605          DOI: 10.1158/2159-8290.CD-18-0044

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  48 in total

Review 1.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

2.  A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.

Authors:  Joaquim Calbo; Erwin van Montfort; Natalie Proost; Ellen van Drunen; H Berna Beverloo; Ralph Meuwissen; Anton Berns
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

3.  UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.

Authors:  Jake Wang; Curtis J Perry; Katrina Meeth; Durga Thakral; William Damsky; Goran Micevic; Susan Kaech; Kim Blenman; Marcus Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2017-06-08       Impact factor: 4.693

4.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Authors:  Sheng Yu Ku; Spencer Rosario; Yanqing Wang; Ping Mu; Mukund Seshadri; Zachary W Goodrich; Maxwell M Goodrich; David P Labbé; Eduardo Cortes Gomez; Jianmin Wang; Henry W Long; Bo Xu; Myles Brown; Massimo Loda; Charles L Sawyers; Leigh Ellis; David W Goodrich
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

5.  Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Authors:  Paula J Kaplan-Lefko; Tsuey-Ming Chen; Michael M Ittmann; Roberto J Barrios; Gustavo E Ayala; Wendy J Huss; Lisette A Maddison; Barbara A Foster; Norman M Greenberg
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

6.  A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.

Authors:  Anthony Pajot; Marie-Louise Michel; Nicolas Fazilleau; Véronique Pancré; Claude Auriault; David M Ojcius; François A Lemonnier; Yu-Chun Lone
Journal:  Eur J Immunol       Date:  2004-11       Impact factor: 5.532

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

Authors:  Henrik Jespersen; Mattias F Lindberg; Marco Donia; Elin M V Söderberg; Rikke Andersen; Ulrich Keller; Lars Ny; Inge Marie Svane; Lisa M Nilsson; Jonas A Nilsson
Journal:  Nat Commun       Date:  2017-09-27       Impact factor: 14.919

9.  Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.

Authors:  M A King; L Covassin; M A Brehm; W Racki; T Pearson; J Leif; J Laning; W Fodor; O Foreman; L Burzenski; T H Chase; B Gott; A A Rossini; R Bortell; L D Shultz; D L Greiner
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

10.  The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Authors:  Katrina Meeth; Jake Xiao Wang; Goran Micevic; William Damsky; Marcus W Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2016-08-03       Impact factor: 4.693

View more
  78 in total

Review 1.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

2.  A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

Authors:  David J DiLillo; Kara Olson; Katja Mohrs; Thomas Craig Meagher; Kevin Bray; Olga Sineshchekova; Thomas Startz; Jessica Kuhnert; Marc W Retter; Stephen Godin; Prachi Sharma; Frank Delfino; John Lin; Eric Smith; Gavin Thurston; Jessica R Kirshner
Journal:  Blood Adv       Date:  2021-03-09

Review 3.  Precision oncology in metastatic colorectal cancer - from biology to medicine.

Authors:  Federica Di Nicolantonio; Pietro Paolo Vitiello; Silvia Marsoni; Salvatore Siena; Josep Tabernero; Livio Trusolino; Rene Bernards; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2021-04-16       Impact factor: 66.675

Review 4.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

Review 5.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 6.  Cancer systems immunology.

Authors:  Nathan E Reticker-Flynn; Edgar G Engleman
Journal:  Elife       Date:  2020-07-13       Impact factor: 8.140

Review 7.  Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas.

Authors:  Pranjali P Kanvinde; Adarsha P Malla; Nina P Connolly; Frank Szulzewsky; Pavlos Anastasiadis; Heather M Ames; Anthony J Kim; Jeffrey A Winkles; Eric C Holland; Graeme F Woodworth
Journal:  Glia       Date:  2021-02-27       Impact factor: 7.452

Review 8.  Vector engineering, strategies and targets in cancer gene therapy.

Authors:  Vijayata Singh; Nusrat Khan; Giridhara R Jayandharan
Journal:  Cancer Gene Ther       Date:  2021-04-15       Impact factor: 5.987

Review 9.  Current status and perspectives of patient-derived rare cancer models.

Authors:  Tadashi Kondo
Journal:  Hum Cell       Date:  2020-06-14       Impact factor: 4.174

Review 10.  Beyond immune checkpoint blockade: emerging immunological strategies.

Authors:  Shawn P Kubli; Thorsten Berger; Daniel V Araujo; Lillian L Siu; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2021-03-08       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.